ArticleBMC cancer2025
Comparison of single-port inflatable mediastinoscopic esophagectomy and thoracoscopic esophagectomy in patients with esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimally Invasive Esophagectomy for Esophageal Cancer: Current Evidence and Future Perspectives.Annals of gastroenterological surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveCurrently, the application of single-port inflatable mediastinoscopic esophagectomy in patients with locally advanced esophageal squamous cell carcinoma receiving neoadjuvant chemoimmunotherapy is relatively rare. This study aims to compare the clinical efficacy of single-port inflatable mediastinoscopic esophagectomy with that of thoracoscopic esophagectomy for locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy.
methodsWe retrospectively analyzed the perioperative data of 118 patients who underwent minimally invasive esophagectomy. Among them, 80 patients underwent thoracoscopy esophagectomy, and 38 patients underwent single-port inflatable mediastinoscopy esophagectomy. The number of mediastinal lymph nodes dissected, incidence of postoperative complications, and survival period were compared between the two groups.
resultsThe results revealed that the number of mediastinal lymph nodes dissected was similar between the two groups (p = 0.185); In terms of postoperative complications, the incidence of pneumonia was significantly lower in the single-port inflatable mediastinoscopic esophagectomy group than in the thoracoscopic esophagectomy group (p = 0.038), but the incidence of hoarseness was higher in the single-port inflatable mediastinoscopic esophagectomy group than in the thoracoscopic esophagectomy group (p = 0.049). Moreover, there were no significant differences in recurrence patterns, overall survival, or disease-free survival between the two groups.
conclusionsThe results suggest that single-port inflatable mediastinoscopic esophagectomy is a safe and reliable option for patients with locally advanced esophageal squamous cell carcinoma who have received neoadjuvant chemoimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.